Age stratification reinforced the observed patterns: 74.7% of frontal lobe gliomas in younger patients (<46 years) carried IDH1/2 mutation, whereas 91.4% of temporal lobe and 100% of thalamic/basal ganglia tumors in older patients (≥46 years) belonged to the IDH1/2-wild-type glioma subtype (Fig. 5J). This evidence concerns the gene IDH1 and central nervous system cancer.